anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Primary sclerosing cholangitis is an autoimmune illness affecting the intrahepatic and/or extrahepatic bile ducts that has a varying clinical history and no clear therapy. Recurrence of primary sclerosing cholangitis after transplantation can cause recurring liver failure, decreased survival, and the necessity for retransplant. Here, we explored the incidence of recurrence while also identifying the risk factors of primary sclerosing cholangitis.
MATERIALS AND METHODS: In this retrospective cohort study, we collected demographic and clinical data from patients with a history of primary sclerosing cholangitis after liver transplant between 2011 and 2021. With SPSS software, we compared results in 2 groups of patients (with and without recurrent sclerosing biliary cholangitis) in terms of demographic and clinical variables.
RESULTS: The study included 408 patients. Lower donor age and the occurrence of acute cellularrejection were shown to be key risk factors for recurrence of primary sclerosing cholangitis. Acute cellularrejection showed the best likelihood of predicting primary sclerosing cholangitis recurrence. As the number of acute cellular rejection episodes increased, so did the chance of primary sclerosing cholangitis. Death rate of patients with recurrence of primary sclerosing cholangitis was 40.8% (n = 20 patients) compared with 18.9% (n = 68 patients) in those without recurrence (significant at P < .001).
CONCLUSIONS: The recurrence of primary sclerosing cholangitis had a detrimental effect on survival after liver transplant. Modifiable risk variables have the potentialto affecttherapies on care and prevention of primary sclerosing cholangitis recurrence. Donor age and acute cellular rejection were risk factors for decreased survival and higher primary sclerosing cholangitis recurrence. The use of mycophenolate (Cellcept) increased recurrence, but tacrolimus reduced mortality.
A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
PURPOSE: To provide the compsn. for treating pimples, etc., which contains eicosapentaenoic acid and α-linolenic acid, is useful for treating pimples and has no side effects, such as a skin allergy, and with which the fundamental treatment from the cause is expected. CONSTITUTION: This pimple treating agent compsn. which is useful for treating the pimples and does not induce the side effects, such as skin allergy, and with which the fundamental treatment from the cause is expected and which has an effect of skin beauty making as well by mixing fish oil contg. 18% eicosapentaenoic acid and 57.6% α-linolenic acid, mixing Perilla ocymoides oil of Perilla frutescens (L)., Baritos var, japonica (hassk). Hara species in a range of 0.1 to 1:20 by weight and further, compounding vitamin E as an antioxidant and a suitable amt. of a sweetening agent therewith.
Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m\^2 intravenously q3w plus capecitabine 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
OBJECTIVES: I. Measure blood flow of primary breast lesions and corresponding lymph nodes by Power Doppler Ultrasound (PDU) and compare this information with metastatic potential and patient survival in women with primary breast cancer. II. Correlate intratumor/-nodal blood flow with pathological variables using standard histology and special stains in this patient population. III. Correlate intratumor microvessel density with total tumor blood flow and with the presence of axillary lymph node metastases using this diagnostic method in these patients. IV. Correlate tumor blood flow with various markers of angiogenesis using this diagnostic method in these patients. V. Compare tumor blood flow as measured with PDU before and after contrast enhancement in these patients.

OUTLINE: This is a diagnostic study. Patients receive ultrasound contrast agent IV. An ultrasound probe with Power Doppler facility is swept over the skin surface in a standard fashion before and after contrast enhancement. Blood flow data is acquired over the volume of the mass and/or lymph nodes using a video recorder. The scanning time ranges between 5 to 15 minutes depending on the size and exact location of the breast mass and axillary lymph nodes. Within 1 week of the ultrasound, patients undergo surgery and the mass and axillary lymph nodes are removed.

PROJECTED ACCRUAL: Approximately 200 patients will be accrued for this study within 1 year.
Malnutrition is a common problem among hospitalized older patients. Peripheral parenteral nutrition (PN) can improve patient outcomes but can also lead to complications that affect future treatment. Older inpatients, in particular, are expected to be prone to these catheter-related complications. However, the impact of peripheral PN on older inpatients has been rarely investigated. In the current study, the impact of PN on short peripheral catheters (SPCs) was evaluated by comparing signs and symptoms at the time of catheter removal between 22 patients with PN and 27 without. In addition to external clinical assessment, sonographic investigations of the SPC site were performed. The prevalence of external signs and symptoms of complications was similar between the patients (all P > 0.05). However, subcutaneous edema was found by ultrasound in > 80% of patients with PN, compared with 55.6% of those without PN (P = 0.051). Unlike cases without PN, all patients with PN who presented with external signs and symptoms developed subcutaneous edema (P = 0.022). Multivariate analysis demonstrated that administration of PN was independently associated with subcutaneous edema (adjusted odds ratio = 6.88, 95% confidence interval = 1.083-75.486, P = 0.040). For several decades, phlebitis has been the primary focus of complications related to peripheral PN in clinical settings. However, our results imply that peripheral PN causes subcutaneous edema, which can lead to catheter failure in older inpatients. This study contributes to understanding the etiology of catheter failure during peripheral PN in this population.
This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
OBJECTIVES: I. Study the effectiveness of mitoxantrone in patients with metastatic, hormone refractory prostate cancer. II. Assess the side effects of mitoxantrone in this patient population. III. Determine whether filgrastim (granulocyte colony-stimulating factor; G-CSF) treatment can overcome chronic bone marrow suppression and facilitate a dose intensive mitoxantrone chemotherapy regimen in this patient population.

OUTLINE: This is a dose escalation study. Patients receive a 30 minute intravenous infusion of mitoxantrone once a week on day 1. On days 2-6 of each week, patients receive subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF). Treatment continues for patients who respond to therapy and exhibit no disease progression. Dose escalation proceeds until the maximum tolerated dose (MTD) of mitoxantrone with G-CSF support is determined. The MTD is defined as the dose preceding that at which 2 or more patients experience dose limiting toxicity. After the MTD is determined, an additional 20-40 patients are enrolled at this dose level to examine their response to this therapy.

PROJECTED ACCRUAL: Approximately 12-24 patients will be accrued for the phase I portion of this protocol. An additional 20-40 patients may be accrued for the phase II portion of this study.
Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 \& 15. The dose of veltuzumab remains the same for all patients.
<P>PROBLEM TO BE SOLVED: To provide an anti-periodontal disease medicine which inhibits the activity of a trypsin-like protease produced by Porphyromonas gingivalis, further inhibits the activities of the trypsin-like protease and a collagenase produced by the bacterium, and can effectively prevent and treat the periodontal disease.  <P>SOLUTION: This anti-periodontal disease medicine contains an extract which is obtained by extracting one or more galenicals selected from the group consisting of Apocynum venetum L., the stamens of Nelumbunucifera Gaertn., and Coleus scutellarioides (L.) Benth. and has an action for inhibiting the activity of a trypsin-like protease produced by Porphyromonas gingivali, as an active ingredient. The anti-periodontal disease medicine contains an extract which is obtained by extracting one or more galenicals selected from the group consisting of Apocynum venetum L., the stamens of Nelumbunucifera Gaertn., and Coleus scutellarioides (L.) Benth. and has an action for inhibiting the activities of the trypsin-like protease and a collagenase produced by the Porphyromonas gingivali, as an active ingredient.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Endoscopic ultrasound guided drainage -Nagi Bi Flanged metal stent--16mm diameter 2cm long with co Axial double pig tail stent used for drainage of walled of necrosis. Intra and post prodecural complications will be noted, a plane CT screening abdomen will be performed with in 48 to 72 hours to document the size of collection.
The primary objective of this study is to test the hypothesis that the combination of Mitoxantrone, Prednisone and Sorafenib in taxane-refractory patients with metastatic hormone refractory prostate cancer (mHRPC) will result in an improvement of the median time to progression (TTP). Since the median (i.e 50% of patients) TTP for Mitoxantrone/Prednisone is 3 months, our hypothesis is that 70% will have not progressed at 3 months with this investigational combination. Progression will be assessed by radiologic imaging criteria.

The early stopping point is 21 subjects. If 10 or fewer subjects with tumor favorable response are observed when 21 subjects are accrued then the null hypothesis is accepted and the trial is terminated. If 16 or more subjects with tumor favorable response are observed when 21 subjects are accrued then the alternative hypothesis is accepted and the trial is terminated. The probability of early stopping under the null is 0.51, and under the alternative is 0.39. If the trial progresses until 42 subjects are evaluated and 24 or more subjects with favorable response are observed then the null hypothesis is rejected. This design minimizes the average sample number under the null, which is 31.2.
A stabilized oral pharmaceutical bead dosage form of sodium iodide I-131 is described. The sodium iodide I-131 is dissolved in a polymer film and the polymer film is applied by conventional coating technology which affixes the sodium iodide I-131 to inert substrate beads. The film also stabilizes the sodium iodide I-131 from chemical degradation. The utility of the bead dosage form is that it provides a decreased radiation hazard over that of handling a sodium iodide I-131 liquid. At the time of manufacture a specified amount of sodium iodide I-131 is applied to the substrate beads. The sodium idoide I-131 containing beads are then stored appropriately until dispensed by the pharmacist or physician. The key advantage of this system is that dispensing flexibility is maintained because as the sodium iodide I-131 undergoes radioactive decay the pharmacist or physician can compensate for the loss by dispensing a larger quantity of the coated beads to constitute the prescribed sodium iodide I-131 dose. Then just prior to patient administration, the beads can be filled into a single hard gelatin capsule of if the patient prefers, the beads can be dispensed in water, orange juice, apple sauce or any suitable liquid or food intended for oral administration. This dosage form described herein minimizes the radiation hazard from the time of manufacture to the time of administration, provides dosing flexibility to the pharmacist and physician and offers the patient numerous options in terms of dosage form administration.
PURPOSE:To provide a production method of a porous ceramics material in which pores are uniformly formed in a connected state and intrusion of osteoblast into pores is made easy. CONSTITUTION:Combustible granular particles having 50-300mum average particle diameter (such as polymethylmethacrylate and polypropylene) are coated with a binder (acryl resin or the like), and an aggregate of the particles is housed in a molding die and pressed under 20-500kgf/cm pressure so that the surface of each particle is fixed in a contact state with the surface of adjacent particles (three-dimensional fixing or the like). Then intergranular spaces among particles are filled with a slurry prepared by suspending a calcium phosphate powder (hydroxyapatite or the like), which is dried and solidified. Then the formed body is heated at 300-700 deg.C to remove the combustible granular particles and the binder by hydrolysis. Then the obtd. body is heated at 900-1300 deg.C to sinter the calcium phosphate powder.
The efficacy of bendamustine hydrochloride was evaluated in a single arm study of 100 patients with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Patients were included if they relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab. All patients received bendamustine hydrochloride intravenously at a dose of 120 mg/m2, on Days 1 and 2 of a 21-day treatment cycle. Patients were treated for up to 8 cycles.

The median age was 60 years, 65% were male, and 95% had a baseline WHO performance status of 0 or 1. Major tumor subtypes were follicular lymphoma (62%), diffuse small lymphocytic lymphoma (21%), and marginal zone lymphoma (16%). Ninety-nine percent of patients had received previous chemotherapy, 91% of patients had received previous alkylator therapy, and 97% of patients had relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab.

Efficacy was based on the assessments by a blinded independent review committee (IRC) and included overall response rate (complete response + complete response unconfirmed + partial response) and duration of response (DR) as summarized in Table 6.
The present invention discloses a medicament for preventing and treating stiff lump caused by phlebitis and injection. The medicament contains anisodamine hydrobromide, carbomer-940, glycerol, laurocapram, water, etc. The medicament is in a gelatin shape. The medicament is directly coated on the skin. The medicament has the advantages of convenient use, lasting medicament effect, strong permeability of the medicament, and good function effect. The medicament is not easily volatilized. The medicament can effectively treat stiff lump caused by phlebitis and injection.
BACKGROUND: Autism Spectrum Disorder (ASD) is a pervasive neurodevelopmental disorder that can significantly impact an individual's ability to socially integrate and adapt. It's crucial to identify key factors associated with ASD. Recent studies link both birth asphyxia (BA) and febrile seizures (FS) separately to higher ASD prevalence. However, investigations into the interplay of BA and FS and its relationship with ASD are yet to be conducted. The present study mainly focuses on exploring the interactive effect between BA and FS in the context of ASD.
METHODS: Utilizing a multi-stage stratified cluster sampling, we initially recruited 84,934 Shanghai children aged 3-12 years old from June 2014 to June 2015, ultimately including 74,251 post-exclusion criteria. A logistic regression model was conducted to estimate the interaction effect after controlling for pertinent covariates. The attributable proportion (AP), the relative excess risk due to interaction (RERI), the synergy index (SI), and multiplicative-scale interaction were computed to determine the interaction effect.
RESULTS: Among a total of 74,251 children, 192 (0.26%) were diagnosed with ASD. The adjusted odds ratio for ASD in children with BA alone was 3.82 (95% confidence interval [CI] 2.42-6.02), for FS alone 3.06 (95%CI 1.48-6.31), and for comorbid BA and FS 21.18 (95%CI 9.10-49.30), versus children without BA or FS. The additive interaction between BA and FS showed statistical significance (P < 0.001), whereas the multiplicative interaction was statistically insignificant (P > 0.05).
LIMITATIONS: This study can only demonstrate the relationship between the interaction of BA and FS with ASD but cannot prove causation. Animal brain experimentation is necessary to unravel its neural mechanisms. A larger sample size, ongoing monitoring, and detailed FS classification are needed for confirming BA-FS interaction in ASD.
CONCLUSION: In this extensive cross-sectional study, both BA and FS were significantly linked to ASD. The coexistence of these factors was associated with an additive increase in ASD prevalence, surpassing the cumulative risk of each individual factor.
Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
The invention belongs to the medical field and relates to an application of 4-dimethyl amino nitrogen-5-hydroxy-formyl-hexyl amine for preparing an anti-human immunodeficiency virus (HIV) latent medicine. The compound has the effect on inducing activation of HIV latent cells, and the compound can be added into a cell culture fluid to induce activation of the HIV latent cells. The compound can be combined with a methyltransferase inhibitor or cell factors or an NF-kB signal activator to form an anti-HIV medicine composition; and the compound can also be combined with the existing HIV medicines to better inhibit and eliminate HIV viruses. Compared with the similar compounds, the compound of the invention has better effect on inducing activation of the HIV latent cells and lower cell toxicity. Especially, the compound can be combined with antiretroviral agents to kill the activated cells of latent infection, thereby accelerating the elimination of a latent virus reservoir. The invention provides a new method and way for thoroughly curing the acquired immune deficiency syndrome (AIDS).
Pregnant women with type 2 diabetes mellitus (T2DM) are at increased risk for miscarriages, birth defects, large infants, and stillbirths. Maintaining blood sugars in the normal range decreases these pregnancy complications. Currently, insulin is the primary medication used to treat pregnant women with T2DM. However, it is administered by injection several times a day and compliance is low in health disparity populations with high rates of obesity and diabetes. Insulin also has the potential to lead to dangerously low blood sugars. Metformin is a medication than can be administered as pills and is not associated with dangerous low blood sugars. In addition, this insulin sensitizer is the medication of choice for women who are obese and have T2DM outside of pregnancy. We hypothesize that metformin will achieve similar levels of blood sugar control compared to insulin. In doing so, metformin will prevent the increased risk of pregnancy complications associated with T2DM in pregnancy. The aims of this study is to determine if in pregnant women with T2DM, metformin achieves similar glycemic control, and similar maternal and neonatal outcomes when compared to insulin. We propose a pilot study of a randomized, controlled trial of metformin versus insulin in the treatment of T2DM during pregnancy.
Gas-filled microbubbles can be synthesized using a continuous flow chamber and a sonicator. The resulting microbubble solution can be size-sorted for a particular application, such as injection into a patient for gas delivery thereto. The microbubble solution may be concentrated to have greater than 50% volume gas while maintaining microbubble sizes below 10 μm. Control of the microbubble generation process can yield highly stable microbubbles. The microbubbles may retain over half of their original gas payload for over three weeks while exhibiting minimal change in microbubble size. The systems, methods, and devices described herein thus allow for continuous or batch-wise continuous production of gas-filled microbubbles that readily release their gas payload when introduced into an under-saturated or de-saturated solution.
A traditional Chinese medicine for treating active-stage rheumatoid arthritis is disclosed. The traditional Chinese medicine is characterized by comprising 8-10 g of orientvine vine, 12-15 g of Chinese clematis root, 9-12 g of pilose antler, 12-15 g of barbary wolfberry fruit, 12-15 g of astragalus propinquus, 12-15 g of scutellaria baicalensis, 12-15 g of red peony root, 18-20 g of honeysuckle bud and flower, 9-12 g of anemarrhena asphodeloides, 9-12 g of honeysuckle stem, 9-12 g of rehmannia glutinosa, 3-6 g of radix angelicae pubescentis and 5-8 g of cassia twig. Medicines in the formula of the traditional Chinese medicine are all natural traditional Chinese medicines. Materials are easily available. The traditional Chinese medicine is simple in formula and preparing method, and low in preparation cost. The traditional Chinese medicine is simple in compatibility. Medicines in the formula of the traditional Chinese medicine are all natural traditional Chinese medicines and are convenient to obtain and use. The traditional Chinese medicine is simple in preparing method, good in taking and treatment effects and low in medicine price.